To our knowledge, advanced pancreatic cancer patients tend to have larger tumor burdens than patients diagnosed with other cancer types, therefore, instead of applying monotherapy of neoantigen vaccination, chemotherapy or ICI (i.e. anti-PD-1) therapy were scheduled to several patients (P01 and P07) to maximize the clinical benefits for them. The gene discussed is PDCD1; the disease is cancer.